title: A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis.
abstract: OBJECTIVE
  This study compares the efficacy and safety of ondansetron alone with that of ondansetron plus dexamethasone in the prevention of emesis induced by high-dose cisplatin (> or = 100 mg/m2).
  
  
  METHODS
  This multicenter study used a randomized, double-blind, parallel-group design. Chemotherapy-naive patients were randomized to receive intravenous (IV) ondansetron (Zofran, Cerenex Pharmaceuticals, Research Triangle Park, NC) 0.15 mg/kg for three doses every 4 hours beginning 30 minutes before cisplatin administration either alone or in combination with dexamethasone 20 mg administered 45 minutes before cisplatin. Cisplatin (> or = 100 mg/m2) was administered as a single infusion (< or = 3 hours). Patients were monitored for emetic episodes (EEs), adverse events, and laboratory safety parameters for 24 hours after cisplatin administration.
  
  
  RESULTS
  A total of 275 patients were enrolled. Of these, 245 were assessable for efficacy. Patients who received ondansetron plus dexamethasone had a higher complete antiemetic response rate (61% v 46%, P = .02) and less nausea (posttreatment visual analog scale mean 18.2 v 32.8, P < .001) than did those who received ondansetron alone. The time to the first EE was longer for patients in the group that received ondansetron plus dexamethasone (P = .005). Headache (12%), diarrhea (2%), and abdominal colic (1%) were the most common antiemetic-related adverse events reported. The incidence of adverse events was similar between the treatment groups.
  
  
  CONCLUSIONS
  IV ondansetron in combination with dexamethasone is safe and more effective than ondansetron alone in the prevention of emesis induced by high-dose cisplatin.
authors.affiliation: Boston University Medical Center, MA.
authors.forename: P J
authors.initials: PJ
authors.lastname: Hesketh
authors.forename: W H
authors.initials: WH
authors.lastname: Harvey
authors.forename: W G
authors.initials: WG
authors.lastname: Harker
authors.forename: T M
authors.initials: TM
authors.lastname: Beck
authors.forename: T
authors.initials: T
authors.lastname: Ryan
authors.forename: L J
authors.initials: LJ
authors.lastname: Bricker
authors.forename: J A
authors.initials: JA
authors.lastname: Kish
authors.forename: W K
authors.initials: WK
authors.lastname: Murphy
authors.forename: J D
authors.initials: JD
authors.lastname: Hainsworth
authors.forename: B
authors.initials: B
authors.lastname: Haley
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy; D017294:Ondansetron / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control*
chemical_list: D017294:Ondansetron; D003907:Dexamethasone; D002945:Cisplatin